TP53 and acute myeloid leukemia: The major advantages of this novel strategy to target BMI-1 in AML by PTC596 were as follows: (1) nanomolar potency; (2) high apoptotic activity against CD34+CD38low/− stem/progenitor cells in primary blasts; and (3) p53 independency in inducing apoptosis.